Trial Profile
A retrospective study determining the reasons and investiagting potential risk factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- 25 Oct 2016 New trial record